Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 10:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 15,129 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Randomized Controlled Study Clear all
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of the Misoprostol Vaginal Priming Insert (MVPI) Prior to Hysteroscopy

NCT00925938
View directory record Official record
Conditions
Cervical Priming
Interventions
misoprostol, placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
2
States / cities
Phoenix, Arizona • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Oct 25, 2026, 10:44 PM EDT
Completed Phase 4 Interventional Results available

An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo

NCT01439815
View directory record Official record
Conditions
Allergic Rhinitis, Allergic Conjunctivitis
Interventions
Fluticasone Propionate Nasal Spray, Saline Nasal Spray
Drug
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Oct 25, 2026, 10:44 PM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Intracervical Balloon Placement With Nitrous Oxide Administration

NCT06498908
View directory record Official record
Conditions
Labor Pain, Induced; Birth
Interventions
Nitrous oxide, Oxygen
Drug
Lead sponsor
Jefferson Drapkin
Other
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 25, 2026, 10:44 PM EDT
Completed Phase 4 Interventional Results available

Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)

NCT03351608
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Neostigmine + Glycopyrrolate, Neostigmine + Atropine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
2 Years to 16 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2021 · Synced Oct 25, 2026, 10:44 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

The Testosterone Trials in Older Men

NCT00799617
View directory record Official record
Conditions
Andropause
Interventions
AndroGel® (testosterone gel), Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
65 Years and older · Male only
Enrollment
790 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2018
U.S. locations
12
States / cities
Birmingham, Alabama • La Jolla, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Oct 25, 2026, 10:44 PM EDT
Recruiting Not applicable Interventional

The Effect of Yoga Practice on Chronic Back Pain

NCT04270617
View directory record Official record
Conditions
Chronic Back Pain
Interventions
Yoga program
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 25, 2026, 10:44 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of FLOSEAL for Hemostasis in Total Knee Arthroplasty

NCT01410240
View directory record Official record
Conditions
Knee Replacement Surgery, Osteoarthritis
Interventions
Standard of Care, FLOSEAL Hemostatic Matrix + Standard of care
Procedure · Drug
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
12
States / cities
Los Angeles, California • Redwood City, California • Englewood, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2014 · Synced Oct 25, 2026, 10:44 PM EDT
Completed Phase 2 Interventional Results available

Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)

NCT02610140
View directory record Official record
Conditions
Mesothelioma
Interventions
Anetumab ravtansine (BAY94-9343), Vinorelbine
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
15
States / cities
La Jolla, California • Aurora, Colorado • Norwich, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Oct 25, 2026, 10:44 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

LMN-101 in a Campylobacter Human Challenge Model

NCT04182490
View directory record Official record
Conditions
Campylobacter Infections
Interventions
LMN-101, Placebo
Biological · Drug
Lead sponsor
Lumen Bioscience, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 25, 2026, 10:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of STABL Virtual Rehabilitation

NCT05556850
View directory record Official record
Conditions
Physical Therapy
Interventions
STABL Virtual Rehabilitation
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 25, 2026, 10:44 PM EDT
Completed Phase 3 Interventional Results available

An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

NCT02544750
View directory record Official record
Conditions
Tuberous Sclerosis Complex, Seizures
Interventions
GWP42003-P
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Year to 65 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Oct 25, 2026, 10:44 PM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of Age With Chronic Idiopathic Constipation

NCT03120520
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
Plecanatide, Matching placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
36
States / cities
Foley, Alabama • Jonesboro, Arkansas • Cerritos, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2019 · Synced Oct 25, 2026, 10:44 PM EDT
Completed Phase 2 Interventional

Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)

NCT00111085
View directory record Official record
Conditions
Aneurysmal Subarachnoid Hemorrhage
Interventions
Clazosentan 1 mg/h, Clazosentan 5 mg/h, Clazosentan 15 mg/h, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
10
States / cities
Peoria, Illinois • Indianapolis, Indiana • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 25, 2026, 10:44 PM EDT
Completed Not applicable Interventional Results available

Electrical Stimulation for the Treatment of Chronic Post-Stroke Shoulder Pain Using the Smartpatch System

NCT01847885
View directory record Official record
Conditions
Post-stroke Shoulder Pain, Hemiplegic Shoulder Pain
Interventions
Smartpatch Peripheral Nerve Stimulation (PNS) System
Device
Lead sponsor
SPR Therapeutics, Inc.
Industry
Eligibility
21 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
Chicago, Illinois • West Orange, New Jersey • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 25, 2026, 10:44 PM EDT
Recruiting Phase 2 Interventional

A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

NCT06920043
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatohepatitis, Non-alcoholic Fatty Liver Disease
Interventions
Efimosfermin, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
28
States / cities
Chandler, Arizona • Mesa, Arizona • Tucson, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 25, 2026, 10:44 PM EDT
Terminated Phase 2 Interventional Results available

A 6-Week Study Of PF-05175157 In Type 2 Diabetes Mellitus

NCT01792635
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PF-05175157, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 16, 2017 · Synced Oct 25, 2026, 10:44 PM EDT
Completed Not applicable Interventional

Ukulele Playing to Improve Cognition in People with Multiple Sclerosis: a Feasibility Study

NCT05792176
View directory record Official record
Conditions
Multiple Sclerosis, Pathologic Processes, Demyelinating Autoimmune Diseases, CNS, Autoimmune Diseases of the Nervous System, Nervous System Diseases, Demyelinating Diseases, Autoimmune Diseases, Immune System Diseases
Interventions
Music Training Intervention, Music Listening
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 25, 2026, 10:44 PM EDT
Completed Phase 3 Interventional Results available

Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women

NCT00755417
View directory record Official record
Conditions
Hot Flashes
Interventions
Gabapentin Extended-Release (G-ER) 1200 mg, Gabapentin Extended-Release (G-ER) 1800 mg, Placebo
Drug
Lead sponsor
Depomed
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
45
States / cities
Birmingham, Alabama • Montgomery, Alabama • Tempe, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2012 · Synced Oct 25, 2026, 10:44 PM EDT
Completed Phase 2 Interventional Results available

ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)

NCT05279417
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
ATI-450 50 mg oral tablet BID, Placebo oral tablet, Methotrexate, ATI-450 20 mg oral tablet BID
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
11
States / cities
El Cajon, California • Encino, California • La Jolla, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 25, 2026, 10:44 PM EDT
Active, not recruiting Phase 3 Interventional

Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)

NCT06553768
View directory record Official record
Conditions
Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)
Interventions
Maralixibat, Placebo
Drug · Other
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
6 Months and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Los Angeles, California • Palo Alto, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 25, 2026, 10:44 PM EDT
Recruiting Phase 2 Interventional

To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva

NCT05090891
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva (FOP)
Interventions
INCB000928, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
2 Years to 99 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
3
States / cities
Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 25, 2026, 10:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers

NCT04527718
View directory record Official record
Conditions
Healthy
Interventions
Placebo, 611
Drug
Lead sponsor
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2022 · Synced Oct 25, 2026, 10:44 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Analgesic Efficacy and Safety of ASP0819 in Patients With Fibromyalgia

NCT03056690
View directory record Official record
Conditions
Fibromyalgia
Interventions
ASP0819, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
24
States / cities
Birmingham, Alabama • El Cajon, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 25, 2026, 10:44 PM EDT
Completed Phase 2 Interventional Results available

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

NCT01287897
View directory record Official record
Conditions
Crohn's Disease
Interventions
PF-04236921 SC injection
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
98
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Oct 25, 2026, 10:44 PM EDT